Skip to content

MIRT and Rotigotine in the Early Stage of PD

Multidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02100176
Acronym
MIRT-RT
Enrollment
40
Registered
2014-03-31
Start date
2013-01-31
Completion date
2014-06-30
Last updated
2014-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Rehabilitation treatment

Brief summary

To test whether a multidisciplinary intensive rehabilitation treatment (MIRT) slowed down the progression of the disease in Parkinson's disease (PD) de novo patients, all treated with Rotigotine, in a randomized controlled study with a 18 months follow-up.

Detailed description

In the last years different rehabilitation treatments have been proposed to address specific motor deficits in Parkinson's disease. Nevertheless, the evidence of a possible neuroprotective action of exercise in PD has been obscured by the facts that all studies were performed in patients in different disease stages and under a variety of pharmacological treatments. Our objective is to test whether a multidisciplinary intensive rehabilitation treatment (MIRT) slowed down the progression of the disease in PD de novo patients, all treated with Rotigotine, in a randomized controlled study with a 18 months follow-up. 40 Patients at the initial stages of PD (H&Y stages 1,5-2) treated only with Rotigotine will be enrolled and randomly assigne into two groups. Patients in group 1 (20 subjects) will be undergone 2 MIRT cycle (at T0 and T3). MIRT consist of a 4-week cycle of physiotherapy that entailed three daily sessions 5 days a week (Frazzitta G. et al., Neurorehabilitation \[30\] 2012, 295-301). Patients in Group 2 (20 subjects) will continue with drug therapy alone. For the group 1, Unified Parkinson's disease rating scale (UPDRS) II, UPDRS III, six-minute walking test (6MWT), Berg Balance Scale (BBS), Timed-up-and-go test (TUG), comfortable and fast gait speed, Self-assessment Parkinson's disease disability scale and L-dopa equivalents will be assessed at Baseline T0, T1 (discharge after the first MIRT cycle), T2 (control at 6 months after discharge), T3 (hospitalization for second MIRT cycle), T4 (discharge after the second MIRT cycle) and T5 (end of the protocol, 18 months); For the group 2, UPDRS II, UPDRS III, six-minute walking test (6MWT), Berg Balance Scale (BBS), Timed-up-and-go test (TUG), confortable and fast gait speed, Self-assessment Parkinson's disease disability scale and L-dopa equivalents will be assessed at Baseline T0, T1 (check-up at 6 months), T2 (check-up at 12 months), T3 (check-up at 18 months).

Interventions

OTHERMultidisciplinary intensive rehabilitation treatment

The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.

DRUGRotigotine

Rotigotine 2-8 mg/24 h

Sponsors

Ospedale Generale Di Zona Moriggia-Pelascini
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Idiopathic Parkinson's disease according to Gelb et al., ability to walk without any physical assistance, no cognitive impairment (MMSE score \> 26), no comorbidity unrelated to Parkinson's disease, no vestibular/visual dysfunction limiting locomotor or balance.

Exclusion criteria

* Atypical Parkinsonisms, cognitive impairment (MMSE \< 26), other comorbidities not related to PD, vestibular/visual dysfunction limiting locomotor or balance.

Design outcomes

Primary

MeasureTime frameDescription
UPDRS total score18 MonthsUnified Parkinson's Disease Rating Scale total score

Secondary

MeasureTime frameDescription
UPDRS II18 MonthsUnified Parkinson's disease Rating Scale II
UPDRS III18 MonthsUnified Parkinson's disease Rating Scale
6MWT18 MonthsSix Minutes Walking Test
TUG18 MonthsTime up and go test
CGS and FGS18 MonthsComfortable and fast gait speed
SPDDS18 MonthsSelf-Assessment Parkinson's Disease Disability Scale
BBS18 MonthsBerg Balance Scale

Other

MeasureTime frameDescription
L Dopa18 Monthslevo-dopa equivalent dosage

Countries

Italy

Contacts

Primary ContactGiuseppe Frazzitta, MD
frazzittag62@gmail.com+39034492552

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026